United States Celiac Disease Treatment Drugs Market Growth, Pipeline Updates & Forecast 2032

Global Celiac Disease Drugs Market is estimated to reach at a CAGR of 8.28% during the forecast period (2024-2031).

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/celiac-disease-drugs-market?kb

Latest M&A Activity

Larger pharmaceutical companies have pursued acquisitions to expand their gastroenterology portfolios, such as AbbVie's acquisition of Finnegan Pharma's portfolio of gluten-related therapies for $1.2 billion, aiming to strengthen the pipeline for celiac and gluten sensitivity treatments.​

Biotech firms specializing in immune modulation therapies, like ImmunoGen, merged with biotech startups focusing on targeted gluten degradation enzymes, to foster innovation in enzyme-based therapies.

Key Players:

Innovate Biopharmaceuticals, Teva Pharmaceutical Industries Ltd, ImmunogenX, LLC, Amgen, ChemoCentryx, Inc, Anokion SA, COUR Pharmaceutical, F. Hoffmann-La Roche Ltd, ImmusanT, Inc, BioLineRx Ltd, and Takeda Pharmaceutical Company Limited,

Growth Forecast Projected:

The Global Celiac Disease Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Celiac Disease Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @: https://www.datamintelligence.com/buy-now-page?report=celiac-disease-drugs-market?kb

Key Segments:

By Enzyme Type: (Distension, Diarrhea, Anorexia, Bloating, Gas, Fatigue, Others)

By Drugs: (First Line of Treatment, Second Line of Treatment)

By Distribution Channel: (Hospital, Research centers, Clinics, Others)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Recent Product Launches and Innovations

Alba Therapeutics announced the launch of AT-100, a novel oral enzyme-based therapy designed to breakdown gluten peptides in the gut before they trigger immune responses. Clinical data highlight significant reduction in gluten-induced tissue damage and symptom relief.​

Celimmune launched its immune modulator, Celiacblock, a biologic monoclonal antibody designed to block the inflammatory response triggered by gluten exposure, currently advancing into Phase 2 trials.​

Several gluten detection and diagnostic tools have been launched, including point-of-care testing kits capable of rapid quantification of gluten levels in food and stool samples, supporting patients' dietary management

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Celiac Disease Drugs producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Celiac Disease Drugs revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/celiac-disease-drugs-market?kb

Clinical Trials and Research

Multiple Phase 2 and Phase 3 trials are ongoing, evaluating enzyme cocktails, peptide-blocking agents, and vaccine-like immunotherapies targeting gluten-specific T-cell responses. Results expected over the next 12-24 months are promising for long-term therapy development.​

Emerging approaches include gut microbiome modulation, personalized immune therapies, and nanotechnology-enabled gluten detoxification strategies

Get 2-Day Free Trial + 50% OFF DataM Subscription@: https://www.datamintelligence.com/reports-subscription?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.